Manuel Iván Girón-Pérez, Guadalupe Herminia Ventura-Ramón, Carlos Eduardo Covantes-Rosales, Alma Betsaida Benitez-Trinidad, Francisco Fabian Razura-Carmona, Leticia Gabriela Marmolejo-Murillo, Carlos Efren Pérez-Arenivas, Jorge Morales-Montor, Karina Janice Guadalupe Díaz-Resendiz
{"title":"Effect of bisphenol-A and bisphenol-S on functional parameters of human leukocytes.","authors":"Manuel Iván Girón-Pérez, Guadalupe Herminia Ventura-Ramón, Carlos Eduardo Covantes-Rosales, Alma Betsaida Benitez-Trinidad, Francisco Fabian Razura-Carmona, Leticia Gabriela Marmolejo-Murillo, Carlos Efren Pérez-Arenivas, Jorge Morales-Montor, Karina Janice Guadalupe Díaz-Resendiz","doi":"10.1080/08923973.2025.2542133","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bisphenol A (BPA) and bisphenol S (BPS) are commonly used in the food industry to manufacture epoxy resins in food packaging. Both compounds are characterized as potent carcinogens and xenoestrogens. However, little is known about their effects on the immune response.</p><p><strong>Objective: </strong>This study evaluated the immunotoxic effects of BPA and BPS (0.1 ng/mL) on human peripheral blood leukocytes.</p><p><strong>Methods: </strong>Leukocytes isolated from human peripheral blood were exposed <i>in vitro</i> to 0.1 ng/mL (0.4 nM) of BPA and 0.1 ng/mL (0.4 nM) of BPS for 0.5, 4, and 24 hours. Apoptosis, mitochondrial membrane potential (ΔΨm), senescence, reactive oxygen species (ROS), and intracellular Ca<sup>2+</sup> flux were subsequently assessed through flow cytometry.</p><p><strong>Results: </strong>Data suggest that <i>in vitro</i> exposure to BPA or BPS does not cause leukocyte death; however, it induces loss of mitochondrial membrane potential (ΔΨm), senescence, as well as ROS production and intracellular Ca<sup>2+</sup> flux.</p><p><strong>Conclusion: </strong>These findings demonstrate that even low concentrations (0.1 ng/ml) of BPA or BPS, levels that have been reported in human blood, can cause alterations in leukocyte function.</p>","PeriodicalId":13420,"journal":{"name":"Immunopharmacology and Immunotoxicology","volume":" ","pages":"621-630"},"PeriodicalIF":3.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopharmacology and Immunotoxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08923973.2025.2542133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Bisphenol A (BPA) and bisphenol S (BPS) are commonly used in the food industry to manufacture epoxy resins in food packaging. Both compounds are characterized as potent carcinogens and xenoestrogens. However, little is known about their effects on the immune response.
Objective: This study evaluated the immunotoxic effects of BPA and BPS (0.1 ng/mL) on human peripheral blood leukocytes.
Methods: Leukocytes isolated from human peripheral blood were exposed in vitro to 0.1 ng/mL (0.4 nM) of BPA and 0.1 ng/mL (0.4 nM) of BPS for 0.5, 4, and 24 hours. Apoptosis, mitochondrial membrane potential (ΔΨm), senescence, reactive oxygen species (ROS), and intracellular Ca2+ flux were subsequently assessed through flow cytometry.
Results: Data suggest that in vitro exposure to BPA or BPS does not cause leukocyte death; however, it induces loss of mitochondrial membrane potential (ΔΨm), senescence, as well as ROS production and intracellular Ca2+ flux.
Conclusion: These findings demonstrate that even low concentrations (0.1 ng/ml) of BPA or BPS, levels that have been reported in human blood, can cause alterations in leukocyte function.
期刊介绍:
The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.
The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.
With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.
Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).